{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Loperamide",
    "query": {
      "intervention": "Loperamide"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 48,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Loperamide&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T09:12:02.521Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00778115",
      "title": "Bioequivalence Study of Loperamide Hydrochloride 2 mg and Simethicone 125 mg Tablet Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Loperamide HCl 2 mg and simethicone 125 mg tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ranbaxy Laboratories Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2004-11",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2008-10-23",
      "last_synced_at": "2026-09-03T09:12:02.521Z",
      "location_count": 1,
      "location_summary": "Saint Charles, Missouri",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00778115"
    },
    {
      "nct_id": "NCT02242656",
      "title": "A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Short Bowel Syndrome",
        "Short Gut Syndrome",
        "SBS",
        "Short Bowel",
        "Short Gut"
      ],
      "interventions": [
        {
          "name": "Opium Tincture USP Deodorized",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marathon Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-02-18",
      "last_synced_at": "2026-09-03T09:12:02.521Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Lima",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02242656"
    },
    {
      "nct_id": "NCT03548051",
      "title": "Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clostridial Infection",
        "Dysbiosis",
        "Probiotic Therapy"
      ],
      "interventions": [
        {
          "name": "Fecal Microbiota Transplantation (FMT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 10,
      "start_date": "2019-01-11",
      "completion_date": "2021-01-13",
      "has_results": true,
      "last_update_posted_date": "2022-05-02",
      "last_synced_at": "2026-09-03T09:12:02.521Z",
      "location_count": 3,
      "location_summary": "Decatur, Georgia • Durham, North Carolina • Nashville, Tennessee",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03548051"
    },
    {
      "nct_id": "NCT01851369",
      "title": "TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphomas",
        "Solid Tumors",
        "NSCLC",
        "Metastatic Colon Carcinoma",
        "Granulosa Cell Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "TRC102",
          "type": "DRUG"
        },
        {
          "name": "CT scan",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Lomotil",
          "type": "OTHER"
        },
        {
          "name": "Prochlorperazine",
          "type": "OTHER"
        },
        {
          "name": "Metoclopramide",
          "type": "OTHER"
        },
        {
          "name": "5-HT3 antagonist",
          "type": "OTHER"
        },
        {
          "name": "Aprepitant",
          "type": "OTHER"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 93,
      "start_date": "2013-07-12",
      "completion_date": "2023-08-01",
      "has_results": true,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-09-03T09:12:02.521Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01851369"
    },
    {
      "nct_id": "NCT06120283",
      "title": "BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Breast Cancer",
        "Metastatic Breast Cancer",
        "Hormone-receptor-positive Breast Cancer",
        "Hormone Receptor Positive Breast Carcinoma",
        "Hormone Receptor Positive Malignant Neoplasm of Breast",
        "HER2-negative Breast Cancer",
        "Hormone Receptor Positive HER-2 Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "BGB-43395",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Elacestrant",
          "type": "DRUG"
        },
        {
          "name": "Anti-Diarrheal Agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BeOne Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 433,
      "start_date": "2023-12-01",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-03T09:12:02.521Z",
      "location_count": 10,
      "location_summary": "Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 7 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06120283"
    },
    {
      "nct_id": "NCT04723056",
      "title": "Zemedy Application for Irritable Bowel Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "IBS - Irritable Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "Use of Zemedy Application",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2021-10-15",
      "completion_date": "2024-03-08",
      "has_results": true,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-09-03T09:12:02.521Z",
      "location_count": 1,
      "location_summary": "Redwood City, California",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04723056"
    },
    {
      "nct_id": "NCT04216329",
      "title": "Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gliosarcoma",
        "Newly Diagnosed",
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Generic Radiation therapy (RT)",
          "type": "RADIATION"
        },
        {
          "name": "Selective serotonin receptor (5-HT3) antagonists",
          "type": "OTHER"
        },
        {
          "name": "Olanzapine",
          "type": "OTHER"
        },
        {
          "name": "Salt tablets",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Anti-diarrheal",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2020-07-07",
      "completion_date": "2028-07-30",
      "has_results": true,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-09-03T09:12:02.521Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04216329"
    },
    {
      "nct_id": "NCT06865677",
      "title": "Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Platinum Resistant Epithelial Ovarian Carcinoma",
        "Recurrent Epithelial Endometrial Carcinoma",
        "Recurrent Epithelial Cervical Carcinoma"
      ],
      "interventions": [
        {
          "name": "Sacituzumab Govitecan",
          "type": "DRUG"
        },
        {
          "name": "EKG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Brain MRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT scans",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Tumor biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Loperamide",
          "type": "DRUG"
        },
        {
          "name": "Octreotide",
          "type": "DRUG"
        },
        {
          "name": "Diphenoxylate/Atropine",
          "type": "DRUG"
        },
        {
          "name": "Antiemetics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 2,
      "start_date": "2025-06-09",
      "completion_date": "2025-07-01",
      "has_results": true,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-09-03T09:12:02.521Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06865677"
    },
    {
      "nct_id": "NCT02858310",
      "title": "E7 TCR T Cells for Human Papillomavirus-Associated Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Papillomavirus Infections",
        "Cervical Intraepithelial Neoplasia",
        "Carcinoma In Situ",
        "Vulvar Neoplasms",
        "Vulvar Diseases"
      ],
      "interventions": [
        {
          "name": "E7 TCR cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "EKG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Chest CT and MRI or PET",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "PFT",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Granisetron",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron",
          "type": "DRUG"
        },
        {
          "name": "Droperidol",
          "type": "DRUG"
        },
        {
          "name": "Prochlorperazine",
          "type": "DRUG"
        },
        {
          "name": "Diphenoxylate HCL",
          "type": "DRUG"
        },
        {
          "name": "Atropine sulfate",
          "type": "DRUG"
        },
        {
          "name": "Codeine sulfate",
          "type": "DRUG"
        },
        {
          "name": "Loperamide",
          "type": "DRUG"
        },
        {
          "name": "Indomethacin",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine HCL",
          "type": "DRUG"
        },
        {
          "name": "Hydroxyzine HCL",
          "type": "DRUG"
        },
        {
          "name": "Meperidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DIAGNOSTIC_TEST",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 224,
      "start_date": "2017-01-27",
      "completion_date": "2025-07-02",
      "has_results": true,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-09-03T09:12:02.521Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • New Brunswick, New Jersey",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02858310"
    },
    {
      "nct_id": "NCT02018653",
      "title": "CASAD for Severe Diarrhea in the Emergency Department",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer",
        "Diarrhea"
      ],
      "interventions": [
        {
          "name": "Calcium Alumina-Silicate (CASAD)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2013-12",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2018-07-26",
      "last_synced_at": "2026-09-03T09:12:02.521Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02018653"
    }
  ]
}